Q-omics provides the consensus-scored SLC46A3 profile across patient tissues and cancer cell-line models. SLC46A3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC46A3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SLC46A3 RNA expression shows 18,659 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where SLC46A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC46A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC46A3 survival associations across molecular data types. SLC46A3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC46A3 RNA expression–survival associations across cancer types. High SLC46A3 expression shows unfavorable associations in BLCA and UVM, but favorable associations in KIRP, LIHC, LUAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC46A3 RNA expression.
This table summarizes SLC46A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC46A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC46A3 shows lower tumor expression in COAD, LIHC, LUSC, THCA, LUAD and READ. The COAD box plot shows higher SLC46A3 RNA expression in normal versus tumor tissue (log2 FC = −1.975, t-test p < 0.001).
This table shows molecular features associated with SLC46A3 in patient tissues and cancer cell lines. In patient samples, SLC46A3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC46A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
